Our mission

People with migraine deserve to reclaim their lives

Reduce brightness?
Turn on Migraine Friendly Mode
A young woman controls her implant with a remote control in her hand.
Logo Salvia figurative mark round - diapositive
Salvia Bioelectronics

Pioneering neuromodulation therapy for chronic migraine


Salvia BioElectronics is pioneering neuromodulation therapy aiming to transform the migraine treatment landscape. Designed to provide meaningful relief, MySalvia Therapy features an ultra-thin implant that comprehensively targets key nerves involved in migraine.

Salvia is driven by the belief that people with chronic migraine deserve the opportunity to reclaim their lives. Founded in 2017 and headquartered in Eindhoven, The Netherlands, Salvia is led by a team of industry veterans with extensive experience in medical devices and neuromodulation. Active in the United States, Europe and Australia, the company is advancing clinical development with the support of leading investors. Salvia is also exploring the potential of its technology for the treatment of cluster headache.

Salvia’s migraine therapy is currently being evaluated in clinical studies. It has not yet been approved for commercial use. No claims are made regarding its safety or effectiveness.

Team

Meet our team

Salvia BioElectronics has experienced remarkable growth over the past seven years. We now have 50+ colleagues from all over the world, representing 17 nationalities. Our home is High Tech Campus Eindhoven, also known as the smartest square kilometer in Europe, where more than 300 high-tech companies are developing the technologies of the future.

Our team
NEWS

Salvia BioElectronics secures $60M in oversubscribed Series B to bring its pioneering migraine therapy to market

Salvia BioElectronics, a clinical-stage medical device company pioneering neuromodulation therapy for people with chronic migraine, today announced the successful completion of a $60 million (€53 million) Series B financing round.

About

It is not “just a headache”

Migraine affects more than one billion people worldwide each year and is the leading cause of disability in people under 50. Cluster headache, which causes excruciating pain behind the eye, is a rare neurological disorder affecting 1 in 1000 people. Read more about both conditions we address with our bioelectronic solution.

Jobs

Join our team

Our team is growing and we are always looking for passionate and talented individuals who want to be part of our mission to give people with migraine a better life.

We also encourage open applications; please submit yours here!

Acquisition is not appreciated.

View all jobs

Information Technology (IT) Specialist

You will play a key role in ensuring that our IT infrastructure is secure, efficient, and aligned with the stringent regulatory requirements of the medical device industry. This is an exciting opportunity to contribute to a fast-paced, purpose-driven company at the forefront of neuromodulation technology.

View job

Financial Controller

As Financial Controller, you will play a key role in strengthening financial oversight, preparing for external audits, and supporting the implementation of a new ERP system. This is a pivotal position in professionalizing the finance function, enhancing internal controls, and building scalable, efficient processes that enable future growth, all within the dynamic environment of a fast-paced scale-up.

View job
news & more

Stay informed

Press release

Salvia BioElectronics strengthens Board of Directors with industry leader Rob ten Hoedt

“Joining Salvia’s Board of Directors is a great opportunity to support the advancement of a pioneering medtech approach with the potential to address a significant unmet medical need,” said Rob ten Hoedt, Member of Salvia’s Board of Directors.

Read post
Press release

Salvia BioElectronics secures $60M in oversubscribed Series B to bring its pioneering migraine therapy to market

Salvia BioElectronics, a clinical-stage medical device company pioneering neuromodulation therapy for people with chronic migraine, today announced the successful completion of a $60 million (€53 million) Series B financing round.

Read post
Blog

Founders with a mission: the story behind Salvia BioElectronics

Get to know the people behind Salvia, and the journey that brought them here.

Read post
Meet our investors

Meet our investors

Logo BOM
Logo Dolby Family
Logo European Innovation Council
Logo Inkef
Logo Innovation Industries
Logo InvestNL
Logo Panakès
Logo SHS Capital
Logo Thuja Capital
Figure Salvia in white color

Salvia Insights

Later in 2025, we will provide updates on our latest clinical trials and other developments. Stay informed about Salvia's mission?

We value your privacy and will only use your email to send you updates about Salvia BioElectronics. Your information will always remain confidential and will not be shared with third parties. You can unsubscribe at any time.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.